Author

Bo Wen

University of MichiganORCID 0000-0002-8337-220XUnclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Bo Wen2 papers

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Assay:proteomics· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:development & morphogenesis· 1

Frequent Co-Authors

Duxin SuniD· 3 shared Hanning Wen· 3 shared Chengyi LiiD· 2 shared Hongyi ZhaoiD· 2 shared Jinsong TaoiD· 2 shared Miao He· 2 shared Chunpeng Yang· 1 shared Fang KeiD· 1 shared

Activity by Year

2024-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

Duxin SunORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Albumin-STING Nanoagonist Reprograms HSPCs to Antitumor Neutrophils Enhancing MHC I-Mediated CD8+ T Cell Immunity

Jinsong Tao, Hongyi Zhao, Chengyi Li, Hanning Wen, Fang Ke, Qiuxia Li, Miao He, Bo Wen, Zhongwei Liu, Wei Gao, Duxin Sun

This paper shows that an albumin-STING nanoagonist reprograms hematopoietic stem/progenitor cells into antitumor neutrophils, enhancing CD8+ T cell immunity against tumors.

bioRxiv · Sep 2, 2025 · PreprintImmunology

Proteolysis-targeting vaccines (PROTAVs) for robust combination immunotherapy of melanoma

Qiyan Wang, Ting Su, Furong Cheng, Shurong Zhou, Xiang Liu, Mi Wang, You Xu, Ri Tang, Shimiao Liao, Jordan M. Dailey, Guolan Xiao, Chunpeng Yang, Hanning Wen, Weijia Zheng, Bo Wen, , Guizhi Zhu

This paper introduces PROTAVs, a new vaccine strategy that enhances T cell responses and combination immunotherapy for melanoma by improving antigen processing and cross-presentation.

bioRxiv · Oct 1, 2024 · PreprintBioengineering

Dual Targeting of STING and PI3Kγ Eliminates Regulatory B Cells to Overcome STING Resistance for Pancreatic Cancer Immunotherapy

Chengyi Li, Shuai Mao, Hongyi Zhao, Miao He, Meilin Wang, Zhongwei Liu, Hanning Wen, Zhixin Yu, Bo Wen, Mahamadou Djibo, Jinsong Tao, Ying-Zi Bu, Wei Gao, Duxin Sun

This paper develops a dual-targeting compound that eliminates regulatory B cells and overcomes STING resistance in pancreatic cancer, improving immunotherapy outcomes.

bioRxiv · Feb 14, 2024 · PreprintPharmacology & Toxicology